Rotigotine
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Rotigotine is a dopamine agonist used for Parkinson's disease and restless leg syndrome (RLS) which is available only as a slow-release transdermal patch applied to the skin.[1][2] Rotigotine is also sold under the brand name Neupro.[1][3] Rotigotine is in the same class of drugs as ropinirole and pramipexole.[4]
Theory
Evidence
No clinicial trials have yet been carried out of rotigotine for patients with ME/CFS.
A single study of rotigotine for fibromyalgia had high dropout rates for both the drug and placebo, but did not appear to show a significant improvement in pain or other fibromyalgia symptoms at doses of 4mg or 8mg.[4][5]
There is inconsistent evidence of the effect of rotigotine on fatigue in Parkinson's disease.[6][7]
Clinicians
Risks and safety
Costs and availability
Notable studies
- 2007, The use of rotigotine for treatment of reducing signs and symptoms of fibromyalgia in adults. Summary (not peer reviewed)
See also
Learn more
- Rotigotine - drugs.com
- Rotigotine transdermal - drugs.com
- Rotigotine - MedlinePlus
- Rotigotine - DrugBank Online
References
- ↑ 1.0 1.1 "Rotigotine: Indications, Side Effects, Warnings". Drugs.com. Retrieved February 21, 2022.
- ↑ "Rotigotine Transdermal Advanced Patient Information". Drugs.com. Retrieved February 21, 2022.
- ↑ "Pramipexole: MedlinePlus Drug Information". medlineplus.gov. Retrieved February 21, 2022.
- ↑ 4.0 4.1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066139/
- ↑ https://clinicaltrials.gov/ct2/show/results/NCT00464737
- ↑ https://jamanetwork.com/journals/jamaneurology/article-abstract/785048
- ↑ https://n.neurology.org/content/78/1_Supplement/P06.088.short
